Verastem Oncology (VSTM), which transitioned to a commercial-stage company in 2025 with the launch of Avmapki Fakzynja Co-Pack, is optimistic about driving sustainable growth this year.
Avmapki Fakzynja Co-Pack is a kinase inhibitor combination of avutometinib and defactinib, approved for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer. It was granted accelerated approval by the FDA in May 2025 and is the first-ever FDA-approved treatment for this indication.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.